Summary of generation of NY-ESO-1–specific CD4+ T helper cells
. | . | NY-ESO-1 (peptide-specific IFN-γ-secreting cells/ratio of proliferation) . | . | . | . | . | . | . | . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | HLA class II DRB1 alleles . | 87–98 . | . | 121–132 . | . | 143–154 . | . | 157–170 . | . | |||||||
. | . | Whole CD4 . | CD4+ CD25- . | Whole CD4 . | CD4+ CD25- . | Whole CD4 . | CD4+ CD25- . | Whole CD4 . | CD4+ CD25- . | |||||||
| Healthy donors | ||||||||||||||||
| NC78 | 04,11 | ND | ND | – (18/1.3) | + (212/3.3) | ND | ND | ND | ND | |||||||
| NC155 | 04,11 | – (7/1.2) | – (12/1.1) | – (14/1.1) | – (16/0.9) | – (7/0.9) | – (16/0.8) | – (18/1.0) | + (251/3.1) | |||||||
| NC158 | 04,04 | – (5/1.1) | – (14/1.0) | – (12/1.1) | – (8/0.9) | – (11/1.0) | – (6/1.2) | ND | ND | |||||||
| NC159 | 03,04 | – (10/0.8) | + (137/4.1) | – (10/1.0) | – (5/1.3) | – (13/0.9) | – (9.5/0.8) | – (9/0.9) | – (8/1.0) | |||||||
| NC174 | 04,07 | ND | ND | – (11/1.1) | – (5/0.9) | ND | ND | ND | ND | |||||||
| NC185 | 04,07 | – (12/1.0) | + (152/3.8) | – (7/1.0) | – (9/1.2) | – (11/1.0) | – (6/1.1) | – (7/0.9) | – (12/1.0) | |||||||
| NC198 | 07,09 | – (14/0.8) | + (243/3.5) | – (9/1.1) | – (13/1.2) | – (11/1.0) | – (10/1.1) | ND | ND | |||||||
| NC233 | 04,04 | – (7/1.0) | – (14/1.2) | – (10/0.8) | – (10/0.9) | – (9/1.0) | – (15/1.2) | – (13/1.1) | – (9.5/1.1) | |||||||
| NY-ESO-1 tumor+ Ab- patients | ||||||||||||||||
| NW681 | 13,13 | – (10/0.8) | – (16/0.9) | – (11/1.3) | – (8/1.3) | – (17/1.1) | + (252/3.8) | – (18/1.2) | – (12/0.9) | |||||||
| NW792 | 04,15 | – (17/1.2) | – (20/1.3) | – (12/0.7) | + (173/5.0) | – (19/1.2) | – (14/1.9) | – (11/0.9) | – (13/0.8) | |||||||
| NW1028 | 04,15 | – (6/1.3) | – (9/1.2) | – (11/0.9) | – (10/1.0) | – (11/0.8) | – (8/0.9) | – (9/1.6) | + (201/4.1) | |||||||
| NW1060 | ND | – (7/1.2) | – (11/0.9) | – (10/1.4) | – (7/0.8) | – (9/1.1) | – (10/1.3) | – (5/1.0) | – (13/1.1) | |||||||
| NY-ESO-1 tumor+ Ab+ patients | ||||||||||||||||
| NW2010 | 07,11 | + (168/13) | + (244/4.5) | – (9/1.4) | – (13/0.7) | – (6/1.8) | – (8/0.8) | – (8/1.0) | – (4/1.6) | |||||||
| NW2457 | 04,15 | – (8/1.1) | – (7/1.5) | – (9/0.7) | + (145/3.9) | – (11/1.3) | – (9/1.0) | + (165/4.8) | + (162/7.0) | |||||||
| NW2493 | 07,13 | – (8/1.1) | – (9/1.2) | + (187/3.8) | + (256/5.2) | – (8/1.3) | – (10/1.2) | – (10/1.1) | – (9/1.4) | |||||||
. | . | NY-ESO-1 (peptide-specific IFN-γ-secreting cells/ratio of proliferation) . | . | . | . | . | . | . | . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | HLA class II DRB1 alleles . | 87–98 . | . | 121–132 . | . | 143–154 . | . | 157–170 . | . | |||||||
. | . | Whole CD4 . | CD4+ CD25- . | Whole CD4 . | CD4+ CD25- . | Whole CD4 . | CD4+ CD25- . | Whole CD4 . | CD4+ CD25- . | |||||||
| Healthy donors | ||||||||||||||||
| NC78 | 04,11 | ND | ND | – (18/1.3) | + (212/3.3) | ND | ND | ND | ND | |||||||
| NC155 | 04,11 | – (7/1.2) | – (12/1.1) | – (14/1.1) | – (16/0.9) | – (7/0.9) | – (16/0.8) | – (18/1.0) | + (251/3.1) | |||||||
| NC158 | 04,04 | – (5/1.1) | – (14/1.0) | – (12/1.1) | – (8/0.9) | – (11/1.0) | – (6/1.2) | ND | ND | |||||||
| NC159 | 03,04 | – (10/0.8) | + (137/4.1) | – (10/1.0) | – (5/1.3) | – (13/0.9) | – (9.5/0.8) | – (9/0.9) | – (8/1.0) | |||||||
| NC174 | 04,07 | ND | ND | – (11/1.1) | – (5/0.9) | ND | ND | ND | ND | |||||||
| NC185 | 04,07 | – (12/1.0) | + (152/3.8) | – (7/1.0) | – (9/1.2) | – (11/1.0) | – (6/1.1) | – (7/0.9) | – (12/1.0) | |||||||
| NC198 | 07,09 | – (14/0.8) | + (243/3.5) | – (9/1.1) | – (13/1.2) | – (11/1.0) | – (10/1.1) | ND | ND | |||||||
| NC233 | 04,04 | – (7/1.0) | – (14/1.2) | – (10/0.8) | – (10/0.9) | – (9/1.0) | – (15/1.2) | – (13/1.1) | – (9.5/1.1) | |||||||
| NY-ESO-1 tumor+ Ab- patients | ||||||||||||||||
| NW681 | 13,13 | – (10/0.8) | – (16/0.9) | – (11/1.3) | – (8/1.3) | – (17/1.1) | + (252/3.8) | – (18/1.2) | – (12/0.9) | |||||||
| NW792 | 04,15 | – (17/1.2) | – (20/1.3) | – (12/0.7) | + (173/5.0) | – (19/1.2) | – (14/1.9) | – (11/0.9) | – (13/0.8) | |||||||
| NW1028 | 04,15 | – (6/1.3) | – (9/1.2) | – (11/0.9) | – (10/1.0) | – (11/0.8) | – (8/0.9) | – (9/1.6) | + (201/4.1) | |||||||
| NW1060 | ND | – (7/1.2) | – (11/0.9) | – (10/1.4) | – (7/0.8) | – (9/1.1) | – (10/1.3) | – (5/1.0) | – (13/1.1) | |||||||
| NY-ESO-1 tumor+ Ab+ patients | ||||||||||||||||
| NW2010 | 07,11 | + (168/13) | + (244/4.5) | – (9/1.4) | – (13/0.7) | – (6/1.8) | – (8/0.8) | – (8/1.0) | – (4/1.6) | |||||||
| NW2457 | 04,15 | – (8/1.1) | – (7/1.5) | – (9/0.7) | + (145/3.9) | – (11/1.3) | – (9/1.0) | + (165/4.8) | + (162/7.0) | |||||||
| NW2493 | 07,13 | – (8/1.1) | – (9/1.2) | + (187/3.8) | + (256/5.2) | – (8/1.3) | – (10/1.2) | – (10/1.1) | – (9/1.4) | |||||||
Italics and plus symbols indicate a significant response.
For data in parentheses, the data to the left of the slash represent spots per 50000 presensitized cells in ELISPOT assay. Background to irrelevant peptides was less than 20 spots. Data to the right of the slash repesent the ratio of proliferation to specific peptides was calculated as counts per minute (cpm) of the sample/cpm of background.